Shanghai Fosun Pharmaceutical (02196) plans to repurchase 300 million to 600 million yuan worth of A shares.

Shanghai Fosun Pharmaceutical (02196) announced that, based on confidence in the group's development and recognition of its value, in order to protect the interests of the majority of investors, enhance investor confidence, and taking into account the performance of the company's A shares in the secondary market, as well as the group's financial situation and development prospects, it plans to repurchase some of the domestic listed Renminbi ordinary shares (A shares) through centralized bidding trading. The total amount of funds for the repurchase of A shares is not less than 300 million yuan and not more than 600 million yuan (including the principal amount), with a maximum repurchase price of 30 yuan per share. The repurchase period will be from January 22, 2025 to July 21, 2025 (including the first and last days).